Karyopharm Therapeutics Inc. (KPTIQ) stock
Price, market cap and P/E appear here once daily prices are connected.
How the market prices Karyopharm Therapeutics
Each ratio against its own distribution since 2016, from month-end prices and the figures reported at the time
Karyopharm Therapeutics trades at 0.0× its earnings, against a median of 2.2× since 2016 — cheaper than 100% of the months in between.
The shaded bar covers the 5th to 95th percentile of month-end values since 2016, the darker part the 25th to 75th, the line the median and the dot today. The figure on the right is the percentile today sits at.
Price to sales since 2016
Median 2.2×, today 0.0×
What Karyopharm Therapeutics keeps of every dollar
Trailing twelve months, from revenue down to net income. Grey columns are what comes out.
Margins against the industry
The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.
What it earns on the capital it uses
Trailing twelve months over average capital
How hard the assets work
The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.
What it owes and what covers it
Latest balance sheet, against twelve months of cash generation
Cash and short-term investments exceed every borrowing by $65.10M.
Leverage and liquidity
The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.
Scores and rules of thumb
Academic scores computed from the latest two fiscal years. They are screens, not verdicts.
Piotroski F-Score
Nine yes-or-no tests of profit, leverage and efficiency against last year.
3 of 9 tests passed
Every measure, in full
37 figures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- No dividends
- Fundamentals through
- Jun 30, 2026
- Share price as of
- –
Share statisticsIndustry
- Shares Change (YoY)
- 136.7%
- 11.0%
- Shares Change (QoQ)
- 0.60%
- 0.57%
- Float
- 22M
- 49M
- Shares Held by Insiders
- 3.71%
- 11.3%
- Shares Held by Institutions
- 96.1%
- 56.3%
MarginsIndustry
- Pretax Margin
- -153.3%
- -13.0%
- EBITDA Margin
- -56.2%
- -29.3%
Returns on capitalIndustry
- Return on Assets (ROA)
- -207.9%
- -40.7%
Financial positionIndustry
- Current Ratio
- 0.79
- 3.28
- Quick Ratio
- 0.71
- 2.37
- Interest Coverage
- -1.67
- -6.20
GrowthIndustry
- Revenue Growth (YoY)
- 6.81%
- 5.68%
- Revenue Growth (3Y CAGR)
- -2.39%
- 2.25%
- Revenue Growth (5Y CAGR)
- 6.21%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 1.36
- 0.39
- Revenue Per Employee
- $643.08K
- $405.05K
- Profits Per Employee
- -$985.70K
- -$704.12K
- Employee Count
- 228
- 75
Income statement (TTM)Industry
- Pretax Income
- -$224.77M
- -$14.83M
Balance sheetIndustry
- Net Cash (Debt)
- $65.10M
- $15.31M
- Net Cash Per Share
- $2.87
- $0.72
- Equity (Book Value)
- -$330.17M
- $49.40M
- Book Value Per Share
- -$14.56
- $1.45
- Tangible Book Value
- -$330.17M
- $23.58M
- Working Capital
- -$27.86M
- $74.34M
Cash flow (TTM)Industry
Taxes and interestIndustry
- Interest Expense
- $49.32M
- $3.07M
- Income Tax
- -$32.00K
- $77.43K
Scores and fair valueIndustry
- Piotroski F-Score
- 3
- 4
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?